Losartan increases bradykinin levels in hypertensive humans

What Was Tested

This randomized controlled trial paper looks at Angiotensin II and Bradykinin.

Studies in animals and humans indicate a role for kinins in the actions of angiotensin type 1 (AT1) receptor blockers.

However, the effect of these compounds on kinin levels in humans is unknown.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

However, the effect of these compounds on kinin levels in humans is unknown.

Topics PubMed links to this paper include Acrylates, Angiotensin I, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Bradykinin, Chromatography, High Pressure Liquid and Hydroxylation.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Angiotensin II and Bradykinin.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (Circulation), a journal based in United States.

More context: the Angiotensin II compound page and the Bradykinin compound page, all human trials.